<SUBMISSION>
<ACCESSION-NUMBER>0001140361-07-008820
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070501
<ITEMS>2.02
<ITEMS>9.01
<FILING-DATE>20070501
<DATE-OF-FILING-DATE-CHANGE>20070501
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>BIOSANTE PHARMACEUTICALS INC
<CIK>0001023024
<ASSIGNED-SIC>2836
<IRS-NUMBER>582301143
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-31812
<FILM-NUMBER>07806813
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
<PHONE>8474780500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>111 BARCLAY BLVD STE 280
<CITY>LINCOLNSHIRE
<STATE>IL
<ZIP>60069
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>BEN ABRAHAM TECHNOLOGIES INC
<DATE-CHANGED>19991027
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>biosante8kforq12007.htm
<DESCRIPTION>8K FOR BIOSANTE FIRST QUARTER 2007 10Q
<TEXT>
<html>
  <head>
    <title>
      8k for BioSante first quarter 2007 10Q
</title>
<!-- Licensed to: EDGARfilings LLC-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Current
      Report</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">__________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
      of
      Report (Date of earliest event reported): </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>May
      1, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Delaware</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>001-31812</strong></font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>58-2301143</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or Other Jurisdiction of Incorporation)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File Number)</font></div>
            </td>
            <td valign="top" width="27%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(I.R.S.
                Employer Identification Number)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 45pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>111
                Barclay Boulevard</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Lincolnshire,
                Illinois</strong></font></div>
            </td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>60069</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                of Principal Executive Offices)</font></div>
            </td>
            <td valign="top" width="40%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(847)
      478-0500</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant&#8217;s
      Telephone Number, Including Area Code)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>N/A</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
      Name or Former Address, If Changed Since Last Report)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
                communications pursuant to Rule 425 under the Securities Act (17
                CFR
                230.425)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
                material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
                240.14a-12)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 14d-2(b) under the Exchange Act (17
                CFR
                240.14d-2(b))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" id="list" width="100%">

          <tr valign="top" style="line-height: 1.25;">
            <td align="right" style="width: 36pt;"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings 2, serif">&#163;&#160;&#160;</font></td>
            <td>
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
                communications pursuant to Rule 13e-4(c) under the Exchange Act (17
                CFR
                240.13e-4(c))</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 81pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Section
      2 - Financial Information</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      2.02. Results of Operations and Financial Condition</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      May 1,
      2007, BioSante Pharmaceuticals, Inc. publicly announced its financial results
      for the first quarter ended March 31, 2007. For further information, please
      refer to the press release attached hereto as Exhibit 99.1, which is
      incorporated by reference herein. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 45pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      information contained in this Item 2.02 and Exhibit 99.1 hereto </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">shall
      not
      be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange
      Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the
      liability of that section, and shall not be incorporated by reference into
      any
      filings made by </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
      Pharmaceuticals, Inc. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">under
      the
      Securities Act of 1933, as amended, or the Exchange Act, except as may be
      expressly set forth by specific reference in such filing.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Section
      9 - Financial Statements and Exhibits</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item
      9.01. Financial Statements and Exhibits. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Exhibits</em></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="10%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
                No.</font></div>
            </td>
            <td align="justify" valign="top" width="59%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Description</font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="10%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="59%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release issued May 1, 2007</font></div>
            </td>
          </tr>

      </table>
    </div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -0.35pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf by the undersigned hereunto
      duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 216pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      /s/
      Phillip B. Donenberg</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phillip
      B. Donenberg</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 234pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
      Financial Officer, Treasurer and Secretary</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated:
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">May
      1,
      2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>BIOSANTE
      PHARMACEUTICALS, INC.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
      Index</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="bottom" width="11%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
                No.</strong></font></div>
            </td>
            <td valign="bottom" width="41%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Description</strong></font></div>
            </td>
            <td valign="bottom" width="25%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Method
                of Filing</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="11%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
            </td>
            <td align="justify" valign="top" width="41%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                Release issued May 1, 2007</font></div>
            </td>
            <td valign="top" width="25%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furnished
                herewith</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q12007pressrelease.htm
<DESCRIPTION>FIRST QUARTER 2007 PRESS RELEASE
<TEXT>
<html>
  <head>
    <title>
      First Quarter 2007 press release
</title>
<!-- Licensed to: EDGARfilings LLC-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><img src="biosantelogo6.jpg" alt=""><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>FOR
        IMMEDIATE RELEASE </strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
        Amex: BPA</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>BioSante
        Pharmaceuticals Reports</strong></font><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>First
        Quarter 2007 Financial Results</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>LINCOLNSHIRE,
        Illinois - (May 1, 2007)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        ---
        BioSante Pharmaceuticals, Inc. (AMEX: BPA) today reported its March 31, 2007
        cash balance and its financial results for the first quarter ended March
        31,
        2007. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: -4.5pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s cash, cash equivalents and short-term investments as of March 31, 2007
        were approximately $15.1 million, as compared to approximately $11.5 million
        on
        December 31, 2006. The Company&#8217;s cash burn rate </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
        the
        second quarter of 2007 is expected to be approximately $750,000 per month.
        </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
          incurred a net loss of approximately $1.8 million or ($0.08) per share
          for the
          quarter ended March 31, 2007, compared to a net loss of $3.2 million or
          ($0.17)
          per share for the same period in 2006. This decrease was due primarily
          to a
          reduction in business development costs and legal expenses and a decrease
          in
          non-cash </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">stock-based
          compensation</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
          expense.
</font></div><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Recent
        Product Developments and Corporate Highlights</u></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font size="2">As
        previously announced<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        the
        Company</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
        December 2006 received its first U.S. Food and Drug Administration (FDA)
        approval for Elestrin&#8482; (estradiol gel) in the treatment of hot flashes. The
        lower of the two Elestrin doses approved is the lowest dose of estradiol
        approved for the treatment of hot flashes. In November 2006, the Company
        bolstered its cash position and realized another milestone in the
        commercialization of Elestrin by signing an exclusive agreement with Bradley
        Pharmaceuticals, Inc.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (NYSE:
        BDY) for the marketing of Elestrin in the United States. Upon execution of
        the
        agreement, BioSante received $3.5 million. The December FDA approval triggered
        a
        payment of $10.5 million to BioSante. In March 2007, the Company received
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">$7.0
        million of this payment and the rest is to be received by year-end 2007.
        Sales-based milestone payments could bring payments from Bradley to BioSante
        up
        to an additional $40 million over several years. In addition, Bradley has
        agreed
        to pay to BioSante royalties on sales of Elestrin. Bradley is planning a
        mid-2007 launch of the product.</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        December 2006, the Company announced that it </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">initiated
        a Phase III safety and efficacy trial of LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (transdermal testosterone gel) in the treatment of female sexual dysfunction
        (FSD). The double-blind, placebo-controlled Phase III trial will enroll
        surgically menopausal women for a six-month clinical trial, conducted under
        a
        Phase III protocol reviewed by and on file with the FDA.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        February 2007, the Company announced that a new patent was issued covering
        the
        formulations used in Elestrin (estradiol gel), BioSante&#8217;s newly approved
        treatment for moderate to severe vasomotor symptoms associated with menopause
        and LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (transdermal testosterone gel), which recently moved into Phase III clinical
        development for the treatment of female sexual dysfunction. The patent, which
        was issued on April 3, 2007 covering both Elestrin and LibiGel, will expire
        on
        June 25, 2022.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>About
        BioSante Pharmaceuticals, Inc. </em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BioSante
        is developing a pipeline of hormone therapy products to treat both men and
        women. These hormone therapy products are gel formulations for transdermal
        administration that deliver bio-identical estradiol and testosterone. BioSante's
        lead products include Elestrin&#8482; (estradiol gel), developed through FDA approval
        by BioSante, indicated for the treatment of moderate-to-severe vasomotor
        symptoms associated with menopause, and LibiGel</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (transdermal testosterone gel) in Phase III development for the treatment
        of
        female sexual dysfunction (FSD). The current market in the U.S. for estrogen
        and
        testosterone products is approximately $2.5 billion. The transdermal gel
        formulations used in the women's gel products are licensed by BioSante from
        Antares Pharma, which receives a portion of milestone payments and royalties
        on
        such products. The company also is developing its calcium phosphate
        nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu
        and
        biodefense vaccines for toxins such as anthrax, as well as a system for
        delivering drugs via alternative routes of administration. Additional
        information is available online at www.biosantepharma.com.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        news
        release contains forward-looking statements within the meaning of the Private
        Securities Litigation Reform Act of 1995. The statements regarding BioSante
        contained in this news release that are not historical in nature, particularly
        those that utilize terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221;
&#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; &#8220;believes,&#8221; &#8220;plans,&#8221; &#8220;hopes,&#8221; or
        comparable terminology, are forward-looking statements. Forward-looking
        statements are based on current expectations and assumptions, and entail
        various
        risks and uncertainties that could cause actual results to differ materially
        from those expressed in such forward-looking statements. Important factors
        known
        to BioSante that cause actual results to differ materially from those expressed
        in such forward-looking statements are the difficulty of developing
        pharmaceutical products, the success of clinical testing, obtaining regulatory
        and other approvals and achieving market acceptance, and other factors
        identified and discussed from time to time in BioSante's filings with the
        Securities and Exchange Commission, including those factors discussed in
        BioSante's most recent Forms 10-K and 10-Q, which discussion also is
        incorporated herein by reference. All forward-looking statements speak only
        as
        of the date of this news release. BioSante undertakes no obligation to update
        or
        revise any forward-looking statement, whether as a result of new information,
        future events or otherwise.</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        more information, please contact: </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phillip
        Donenberg, BioSante Pharmaceuticals, Inc.; (847) 478-0500;
        donenber@biosantepharma.com</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 9pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    </div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>biosantelogo6.jpg
<DESCRIPTION>LOGO
<TEXT>
begin 644 biosantelogo6.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`'W_
MVP!#``8$!`4$!`8%!04&!@8'"0X)"0@("1(-#0H.%1(6%A42%!07&B$<%Q@?
M&104'2<='R(C)24E%API+"@D*R$D)23_VP!#`08&!@D("1$)"1$D&!08)"0D
M)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D)"0D
M)"3_P``1"`"/`5$#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#QW_A8_C/_`*&C5_\`P*?_`!H/Q(\9#_F9]8_\
M"G_QKFJ&^[7Z$\/2M\*%<]NTGP)\;-;TZUU&SUK4&M[F)9HW.H'H>1D9]*L_
M\*O^/'_07OO_``8G_&OHOX6'/P[\.GJ?[/AY_P"`BM'6/&.@>'Y%BU;6+&PD
M<95;B94+?3-?(SS"I[1QC!:>11\Q_P#"KOCQ_P!!:_\`_!D?\::_PS^/D8.-
M1U.7Z:EC^M?1_P#PM#P5_P!#3HW_`(%I_C5G3O'7AG6)1!IVOZ9<R$XVPW"L
MWY9IO,*RW@O_``$SLCX]\0Q?%_PFC-K-YXC@1>LHN&9%^K`X_6N8_P"%D>,_
M^AGU?_P*?_&OT!NK&VO;9X+B&.6*089'7(-?$_QX^'<'P_\`&#+9*$T^_4SP
MQD\+_>4?ICZUZ&7X^GB'[.I!)E6-7PQX5^,GC#28=6TK6]0FM)B<.;\@\>VZ
ML_QK#\4_A\EN^O:_JD/VHD1[;UFZ?0U[?\`O%^@:7\-+"VO]:L+69&?,<DRJ
MPR>.IKA_VJO$.CZ]!HBZ;J=I>B-W+>1('VC'7@U%"O4GBO9."MZ!8\;_`.%D
M^,O^AGU?_P`"G_QH_P"%C^,_^AHU?_P*?_&N:HKZ'ZM2_E07.E_X6/XS_P"A
MHU?_`,"G_P`:/^%C^,_^AGU?_P`"G_QKFJ*/J]+^5!<Z3_A9'C+_`*&?5_\`
MP*?_`!I?^%D^,?\`H:=7_P#`I_\`&N:^M=?\*/!+>/\`QK8Z1)G[.#YD^./D
M'6HK4Z%*#G**T"YI>'M0^*OBV39HNI>(KPD\ND[[!_P(G%=G#\-/CS(NYM1U
M.//\+ZES^AKZFT;0;#P]I\6GZ=;1VT$2[0JC'X^YJOJ_B_0=!(74M9L+-C_S
MWG52?SKY6IFDI3_=4U;T"Q\R?\*O^/'_`$%K_P#\&1_QI/\`A5_QX_Z"U]_X
M,C_C7T=_PM'P5_T-6C?^!:_XT?\`"T/!7_0U:-_X%I_C2^OU_P#GVON%9'SB
M?AA\=U!+:M?X`R?^)D?\:\TO_'GCC3[V:SN/$FK)+"Y1T%V_!'H<U]JW'Q/\
M%-;RA?%.CDE"`!=+Z?6OA7Q1-'=^)-3EA9)8WN7977D$9Z@UZ>55)8B;C5@O
MN'8O_P#"R/&>/^1GU?\`\"G_`,:/^%C^,_\`H:-7_P#`I_\`&N:HKV_JU+^5
M!<Z7_A8_C/\`Z&C5_P#P*?\`QH_X6/XS_P"AHU?_`,"G_P`:YJBCZM2_E07.
ME_X6/XS_`.AHU?\`\"G_`,:/^%C^,_\`H:-7_P#`I_\`&N:HH^K4OY4%SI?^
M%C^,_P#H:-7_`/`I_P#&C_A8_C/_`*&C5_\`P*?_`!KFJ*/JU+^5!<Z7_A8_
MC/\`Z&C5_P#P*?\`QH_X6/XS_P"AGUC_`,"G_P`:YJBCZM2_E07.F3XD>,BX
M'_"3ZO\`C=/U_.O4+;X:_'*[MX[B'6+]HY%#J?[0(R",CO7A<?\`K%^HK]&_
M#P']@Z=Q_P`N\?\`Z"*\7-JRPS4:<5KY"@?#GB/Q+\0/">KW&D:GXDU6.\@(
M#A;UB*RC\1_&?_0SZO\`^!3_`.-;_P`?N/BKK7;]X/Y5YW7J86C3J48U'%7&
M=+_PL?QG_P!#1J__`(%/_C1_PL?QG_T-&K_^!3_XUS5%;?5J7\J"YTO_``L?
MQG_T-&K_`/@4_P#C1_PL?QG_`-#1J_\`X%/_`(US5%'U>E_*@N=+_P`+'\9_
M]#1J_P#X%/\`XU=T7XB^,)=8L8W\2ZNR-.@93<M@C(]ZXVM#0?\`D.:?_P!?
M$?\`Z$*BMAZ2@[107/O3SY_^?B7_`+ZHJ*BOB2SX`H;[M%#?=K[Y[$'Z!_"S
M_DG?AW_L'P_^@"OGO]K\#_A)]$_Z]G/ZU]!_"O\`Y)UX>_[!\/\`Z"*Q_B)\
M&-!^)=]:WFL3WD3VR%$%NX'!]<BOAL-7C0Q3J3V0SX6V#T%36ES<65Q'/;2/
M%-&P*,AP<^QKZZ_X9,\#?\_>K?\`?Y?\*N:-^S%X%T;4$O,7UX8CN$4\@*`_
M0#FO=K9YAI1T3^X5CT3P?<W-]X4TFYN]QN);2)Y,\%F*`GZ<U\\_M@2QF]\/
MP84SA)&^BY%?1&O^(-,\'Z+)?ZA,MO:6Z]<?D,"OA[XJ^/9_B)XKGU9E9+9%
M,5M&>T?8_4UY>4474Q"J+9$S/3/A?^SKH_CKP;::]<ZI>033LV5C`(X..E<S
M\<?A!8?"Y--:PO;BY^V%U/FCIQ7T'^S>!_PJO3!@???^=>??MA`+#X?./^6C
M_P`JZ,/C*TL=[-RTO:Q1\S!2S!5!))P`*]F^'G[->M^+8(M1U>;^RK*3!12,
MR2#UQV_&H_V;OAW!XM\5OJFHP![+3,-L89#R'[N?YU];:[K-AX8TB?4[UUAM
M;:,L3].PKIS/,YTY^PH;]Q6/(8/V2_!448\V]U:5^[>8H_3%8'B7]DFS:&23
MP_JTZ2C[L-V`RO\`B.E9&L_M;:O)J#G1]'MA:(V%\\DNX]>.!7J?PA^-=E\2
MU>RG@^PZI"-[0[LK(/537GS_`+0HQ]M-Z!H?(/BKPIJO@O5'TS6+-X)U/RY'
M##U4]Q7L'[(]K%+XNU29\%X[;Y<CIDU[/\<?AW:^.?!]R5@']H6:--!)CYN.
MJ_C7SK^SMXL@\*?$5(+YUBAO5,#%N`KYXS7H?77C,%-/=!8^Q?$=W+8:#J%U
M`,RPP.Z#W`K\\=6U2]UG4KF]OIY)IY'9F+G)'/3FOT:E1+F)D<!T=<%>H(->
M-:[^R[X0UG49KN"XO;)I6+/'&P*Y/ID<5Y65XREAI-5.I1\=X'H*,+Z"OK/_
M`(9#\-?]!C4?_'?\*;-^R'X;9#MUK4%/KA:]W^V\+W8'R=L'H/RI<=A^`KW/
MQO\`LNZUX>LI;W0[Q=5CC&YHV79(!_(UX;+"]O*\4BLKHVUE88VGN#7?AL72
MQ'\%B/?OA=^SKH_CWP98Z[<ZI=V\UQG<J*".#77?\,@^'_\`H.7W_?(KRWP'
M^T3K'@+PU;Z'9Z5:7$4&[#NY&>:Z/_AKSQ%_T`M/!]?,->)6I9DYOD>@'6-^
MR%X?"G&N7^?]T5R7BS]E#5=-M9;C0-434-@W&&9"C,/8^M6;/]K[5DG7[;X>
MMFB/!V2D-CVR*^AO!OBJR\;^'[76[$-Y4ZY"MU4]Q7'4Q&.PKYJKT&?GU=V=
MQI]U+:7<+PSQ$JZ,N&4CUKT;X)_"NR^)^I7]I?WD]JMK&KJ8@#G)]ZZS]J_P
MQ!IGB:PUFVA"?;8MLV.A8'_"K?['_P#R'=;.,GR$_F:]BOC93P2K0T8K'5?\
M,@>'?^@[J'Y+36_9`\/!6QKE^3VX6O5OB3XU;P%X5N=<2U%VUN5'EEMN[/O7
MAJ_MC7)X/A.+'K]J_P#L:\2A5Q]:+E3;=AAK7[(<L-N\VCZ^LLH&1%<Q8!]L
M@UX-XF\+ZEX0U.32]6M'M[J/DANCCU7VK[?^%WQ*LOB;H;ZE:P/;M$YCEA<@
M[6KRO]K;P_#)H^F:[%&JSQ2F!VZ94BNK!9C7C65&MJ*QB?#G]F[1O&'@[3M=
MN-4NHIKI!(451@&OINPM5LK&&V#,1#&J`GJ0!BOC;P=^T5XG\(Z%9Z+9V-@]
MK:J%5G4Y(^N:^Q-)NVN]-M;J10K2Q+(<=,D`G%<.:0KQFW6^00/*_&W[-VC>
M-?$=YKESJMW!-=$$J@&%_.O!_C;\*=/^%]UIL%A>7%T+I&=C)C(P:])^)O[1
M7B;P=XTU+1;&QL)(+9PJM*K$],]C7COC_P")FM?%:[T]=3M;:.>%O*B6!2"Q
M8\=37IY?#&049R?[L9E^"?`6N^/M3%CHMGYVWF23HD?U;^E>X:1^R'NB5M5U
M_:YY9+>'A3[,3S^5>Q_"OP/:^!/"5GI\,0^TM&);B0#YGD/)YKB_BM^T-;>`
M-9?1-/T[^T+V%0TI9MJ1Y[?6N>KF.)Q%;V>'`R5_9#\/`<ZYJ!;UV@5A>-_V
M8M#\+>%-3UJ#5[N62R@:55=1M.*S_P#AK[7GY_L"S4?]=&_PK+\4?M.:OXK\
M/W^B3:+:PI>Q&$NLARN?PK6G2S'G7,R=#Q0*#EB>P/IS5_0/^0YI_P#U\1_^
MA"J/.WD8SCWXQ_\`6J]H(_XGFG_]?$?_`*$*^DJ?PG<9]W4445\*:'P#0WW:
M*&^[7WCV,S]`_A7_`,D[\/?]@^'_`-!%<G\6_C;!\+=3LK&33)+XW49D!5PN
MW!YKK/A7_P`DZ\/?]@^'_P!!%?/_`.UM9W%QXHT=H()95%JX+(I..>^!7PV%
MHTZN+Y*FPS;_`.&P[;_H6Y/^_P"*NZ/^UMH][?QV^H:+<VL,A`\U'#!?J*^7
M1IM[D?Z+<?\`?HU=L/#&LZO?1V=GI]U+/,X4!8VY_,<5]#6RO!QA?]17/T%F
MBTWQ%I&)HH[RSNHP0K`,K*W3K7QI\>/AQ;_#WQ4%L5VZ=?(9H5).8R/O+^HQ
M]:^P?!NF3:-X6TK3KC`FM[6..09S\P4`_K7@?[84L(&@1-Q,?-;_`(",?UQ7
MB954E#%*$=F,]&_9OX^%>F?[S_SKS[]L7_4^'O\`??\`E7H/[.'_`"2O3/\`
M>?\`G7GW[8G^J\/?[[_RJ\-_R,?F(W_V3K"&W\#7EVO^LGNB&/T''\ZF_:KU
M&>T^'T-M&2J75TJ.1Z#G%8W[(NO13:)JNC,X\V&83(G?:>I_.NU_:$\(7/BO
MX>W$=G%YES:,+A%'\0'4#WQ4U/<Q]Y]P/B3&.AKO/@=J$VG_`!-T,Q.<2S"-
ML<<&N&E1H9"C*58'!!&"&]"#7K7[-_@N[U[QU::KY+"RTYC(TA'RLW85]+CI
MP6'DY,+'V7<HKVTJGD,A'Z5^=_BB,V'BW4XX6*>5>2!2.H.XFOT%UO48=)TB
M[O;APL4,3.Q)QT%?GAJ]P^L:W>72@R-<3O*B@'+9;@<=\5X600?--O8F9ZSX
M)_:8\3^&;6.SU*&/5K:(;5,C;)`/3/>NZB_;`T[:/.\.W()[*X-?-']GW_\`
MSXW''_3,\4?V??YYL;C_`+]FO6J97@YOF:_$H^G?^&P-(_Z%Z\_[^+6QX4_:
MC\-Z_J4.GW=A=Z>TS!$D<ADR3ZBODH:;?_\`/C<?]^S6_P"#/!.N^)-?LK6Q
MTVY8B96=S&P"`'J3@5SU\KPD8<R?XA<^_P`,CID;6##\\U\0?M`>'(O#GQ,O
MU@58X+H"X5,<`GK^M?;5G#]FM8(6&62-4)]2!7R-^TI+#J'Q8MK964B-(HY1
M]6%>/E$W"N^4;)_A1^SE+XPTZ+6->N7LK&;YHH8^)'7UYZ"O7K7]F#P!`@5[
M:[N#ZO+_`(5Z9HEE!9Z/9V\2A4CA10`,#@"OFSXT?'3Q?H/C2^T31[A+&WLR
M%#!`6<XZ\U:Q&*QE;EISL!Z@/V:/AXIS_9LP_P"VQKNO"GA+2_!FDII6D1/%
M:IR%9B>OUKXT_P"&A_B,?^8\?^_2_P"%?3?P&\5:KXQ\#Q:IJUR;BZ>5E+$8
M&`?05.883%4H7KRNO4#SO]K\?\2_0^/^6C?RK&_8_P#^0[K?_7!/YFMK]K[_
M`)!^A_\`71ZQ?V/?^0]K?_7!/YFNN'_(L8CUG]HX?\6KU+@?>3^=?$(X%?;_
M`.T;_P`DLU+_`'D_G7Q`>E=?#_\`!D3(^I/V/LG1==S_`,_*?^@BM[]J]1_P
MK>(X'%XG]:P?V/?^0-KO_7RG_H(K>_:O_P"2;Q?]?B?UKSZW_(R^970^/E!\
MQ>,<BOT;\/`?V%IW_7M'_P"@BOSD4X<'W'6OT;\.\^']./'-M'_Z"*Z.(OL$
MP/B;X_@'XJZR/^F@_E7/?#RV6Z\<Z!%)T:^AS^#`UUG[1>FS:?\`%'4I)D94
MG"2QL1PX([?2N&\*7ZZ1XFTK4';:EO=Q.Q]@PS^E>IAY*6#Y8]BC]%5`5``,
M`#BO-_$7P"\&>*-8N=4U&VN7N;IM[L)2!GZ5Z%:W*75K%<QL#'*@8>X(KYH^
M+WQD\?\`@3QM?Z;;R1168*M;%XLAE(SD'OZ5\G@Z=6=5QI.S&>BC]F'P`!C[
M)=8_Z[&N;^(?[/G@GPYX*U;5K*VN%N;6W:5"9">17E/_``T]\0_^?RT_[\BJ
M&N?M!>-_$>E7.DWUS;/;72&)U6+!P:]FG@\:I)RG^(CS;D``DCO^?.*OZ!_R
M'-/_`.OF/_T(50&2OMTQ].]7_#__`"&]/_Z^8_\`T(5]%47[IDH^[Z***^%-
MCX!H;[M%*>!7WKV,S]`?A61_PKOP]_V#X?\`T$5T5Q86=VP:XMH96'`+H#BO
MCS0?%OB:WT2RBM?$&H0Q+$@CC1AM4>GTJ_\`\)KXK_Z&74?^_@_PKX^IE53V
MC=R?:(^L/[&TW_GQM?\`OV/\*DAT^SM<M!;0Q$\DH@%?)7_":^+/^AEU+_OX
M/\*8_C+Q1(-A\2:H1Z^8!_2I_LJJ_M![1'U5K?B+2O#EE)>:E>P6L,8W%I&`
M_P#UU\4?&GXC'XC^+'NX-PT^V4Q6P/5E[L?3/]*3Q%I6JZWOEGU>\NW'\-Q(
M6'X`UPD\#VD[Q2*5D7J#7KY;ED:$O:-W8<US[8_9O`_X57IG^^_\Z\^_;$QY
M'A_O^\?^5>:^"_$_B'3M`@@LM<O[6W!.V.-@%'YUD?$C6]6U@68U/4KF]V9V
MF9@=OY5A0R^<<9[6^E[CY];%'X<>.KSX>>)[?6;3YHONSQ9QYD9ZCZU]M>#_
M`!UH?CO38[O3+N*4,N7B8_,A]"*_/O:9F"(I8YZ"NT\+:7JFCRK?6VHW5C-_
M=A8J<>AQUKJS++H5O?3LR>:Q]?:O\'?!&NWK7M]X?MGG8Y+KE<GU.*Z+3-&T
M;PII_P!FL+:WL+6,9(0!1]2>]?-]I\5O&%G`L*ZO+*<8W.`2*YKQ7XA\1^+(
MRE_KU]M/_+-6VK^(%>.LLK3]V<M!^T1U_P"T%\:;;4+23PKX?N/-1CBZN8VR
MI_V`?ZUY+\&HDF^)>@1R*KI]HY5AD?E7+ZII=UID^RX4A3]UAT-3^%[JXLM>
MM;BVGD@G1_ED3^$_XU]!2P<:.&]G3#F/T.&D:=C_`(\K;_OV*7^R=._Y\K;_
M`+]BODP^-?%F?^1EU+_OX/\`"C_A-?%G_0RZE_W\'^%?._V96_F#G1]9_P!D
MZ=_SY6O_`'[%2Q6UM;+^YBBC'^RH%?(Q\:^*\_\`(RZC_P!_!_A5>\\4^*+R
M-HY/$NJ!3W$F/Y4?V35?V@YT?3'CCXC:!X%TR:[U"]B\U5)CA#9=V],5\.>*
M/%%UXF\4W/B"X#"6>7S5!/0`_**T-?\`#VH7+/>/>W%ZYY)F<LV/;-<HRXP"
MIRIP=U>WEV6TZ*NW=BOS'W?\*OB%IOCGPO9307""[2)4GAW?,K`8S6AX@^&G
MA+Q5="ZUC1;:ZN.AD(P3]2*^*_"6F:G9,FH6^H75BS?=\ERI->@1>,/%**`O
MB34QC@'S`:\RME+C4;HR'[1(^@?^%%?#L<_\(U:_FU=3X<\-Z5X6TY+#2+-+
M2V4DB-#D`_C7RQ_PFGBP_P#,S:E_W\'^%)_PFGBP?\S+J(`_Z:#_``K">5UY
M+WIA[1'8_M?'_B7Z'_UT>L;]C[_D.ZU_UP3^9KS/XC:YJ^KQ6JZEJ=Y?*K';
MYYSCZ8JM\-]7U72+R[.G:A<63L@W&!@"1Z'->K'`R6"]C?<F^MSZM_:,P?A7
MJ0]T_G7Q"1\M>I^-/%?B+4?#\\%_K%[<0$@&*1AS]<5Y;CD9Z9KHRG"2H0<9
M/<J]SZA_8\/_`!)M=_Z^4_\`0!6_^U=@_#F+_K\3^M?/7PVUW6-*M[N/2]4N
M+%9'#$0L!GZYJ[\0?$6N:GHP@U'5;N\A,NY4F;C/X5Q5,NF\9[:XO:):'F_<
M#W_+WK[<^!_Q'L?&/A&QMGN(UU*T0130LV"=O&17Q$00,C'N*Z?PEIFH)*-1
MM[VXL3G*M"Y5C^(KOS/`QQ%-7>H^:Q]Q^)O`WASQ>J_VWI5O>%.%9QR/Q%?,
M?[2?@7P_X+OM(BT'3X[(3(Q<*20>?>FQ>,/%,2A1XEU,*!@'>,?B2*XCXC:U
MJ6K3V3:IJ5U>E58(93G%>9@<!5IU4^;1!SH]S^`GQQL+O38?#7B*[6"]MQM@
MN)#A9E^OJ*]GU3PYH'BJ%&U&QLK]"/E9U#D#KP:^`-&T2YU1]T/"J<%^PKT?
M1+S7]"B$5MXCU1%`^ZLIP/H#FKQ>41]ISTIV8>T2/J$_!OP)W\.61)]%Q7+?
M$[X6>#M)\!:W?6>A6D,\-LSQR*.5->0#QMXL(Q_PDFI`#UD'/Z5F>)/%WB6Z
MT2]AN=?OIXGC(>-V!5A^5<U++\1&:;F'.CR0G*CCGO\`G5[0/^0YI_\`U\1_
M^A"J`)"]R"![8J_H'_(<L./^7B/_`-"%?45%^Z?H%S[NHHHKX4V/@&AJ*&K[
MUF1Z5I'_`""K,X_Y9+5+7?$,FCSQQ"W1U9=V2:NZ1_R"K3_KDM<YXTADEO8&
MC1V&S^%<UPPC&4]3FC\0O_";3?\`/FGYU)!XYW.JS6@"_P"R:YC[-/\`\\)?
M^^#4D.GW5PR1I!*-W^S71[.F:<B/2H766,2#YE==P([5R7C6V2.[AN$`W2#!
M]ZZJQADMK&"%R"\:;>*Y3QM.CSV\*,-R<M6%+XM"(?$;?AC_`)`T)'O65X[Y
M%OGGFM7PQ_R!H?QK*\=?<M_K5TOXI7VBMX1TR.XNY+EURD0XXXW5U]_?1:;:
MR7$AP$'`K$\&Q[=+=NY;FCQG(ZZ:J@<2.!14]ZI8;U=C%N/%NH2RL\;HB9X&
M,XK:\/>)'U.4VUT`)!R".AKB<=>*T-#E:/5[9T_OX-:SHQ4;E3@N4[?7+!-2
MT^:,_?494^E<#8W)LKM963)1LD?I7IS*"C#'45Y??QB.]F"G_EH:6&9,#H3X
MWD_Y]1^=!\;OG_CU'YUS"QNYPJ[ZE%G<E<_9Y2/4(:KV4!V1T1\;/S_HH_.K
M=CXTCN)UCGMV3/`8'I7)-970_P"7:7_OD_X5:T[2+ZZN8U$,BKD$DKC%9NG$
MGD1Z-M!8Y.Y2,Y%<#X@LUMM9,2X"NP//UKOE0HJ+D'"A:X?QC+C6,I]Y%&:S
MH?$.&]CMH$5(41<`(!Q^%<GK?B2^LK^2"$HBIT&,YK<T348M2LH]KIYBC:03
MR:L7ND65_('F@1VQ@MTI))2]Y$1]V6IQ0\6:J!_K$_[YKK/#EY+J&FK<3OOD
M)P>,4?\`",:6?^78?F:O6=E%80""%`B`YIU91:LAS:.;\<_ZNV^IJ+P4/](N
M!VVBIO'7^JMOJ:A\%_\`'U<?[@JO^794?A-CQ0!_8\_'<5P/0@>XKO\`Q3_R
M!I_J*\_'WAQW%7A2X'7>"!^XN1_MBK/C,?\`$L7I]^JW@C_4W7^^*M>,_P#D
M%C_?J)?Q#/[1PY`)YQ@\5Z?IT0@M($7H(P,?A7F!'TKU"T'[F+_<7^0JL5L.
M9SGB3Q'<V5V;2U(4K]YL5SUWJ=WJTD8G8,00GIUJ;Q$?^)Q<56TI%DU&W5ON
MF05I3@E"XTO=/0M,L8["QB@C7H`6(ZY-8FO>)YK&\-K:QJ6C^\YKIPH#$#@"
MJ4^C:=/.TKVL;ENI(-<L9+FU,EN<B?%VJ==T?_?-1W'B?4;J"2%VCVN,'"UV
M'_"/Z7_SY0_E5/5M#T^'3IY([6-75>&%:QJ1[&B:.$/`&1DXVFKV@#_B=Z?_
M`-?$?_H0K/!;:I(P#6AH'_(<T_\`Z^(__0A6U7^&S8^[J***^%-#X!H;I10U
M?>F9Z5I/_(*M?^N:U<95/50?PJGH_P#R"[;_`*YK6#XPN[BUN85CD>/<O\+5
MPI7F<]KR.JV)_<'Y4H50?E4#'>O,O[4OO^?N7\ZEM-<U&UD1DN7)]":U]@RN
M0]!U)KE+1GM8T:8=`37F]U+--<R-<9\S=\VX=*])M9#<6L<[(5,B[L>E<AXS
MLT@OHYD7Y9E^;\*F@[.PH;V-[PQ_R!H?QK*\=?=M_K6IX7.=&AS@=>]97CG!
M%OC!YIP_B#^T2^";M%2:V;_6'YP*U_$.FMJ6GR1QC$B_,M<!I]W)8727$389
M3\P/I7?Z9K=IJ<:E)`DO\2,>?P]:*D&G=!.&MSSN6&2)V1U=67U%;WA/1YI[
MP73QE(H^A;^*NR>TMYFW/#&Y]2*=+)!:IEW2)%[$XHE6<ERB]H-NIA;VLLI.
M`J]^]><V=K)JVH>2G61RQ8=JU/$?B(7G^C6S?N@>?]JG>"8U;4))#_"E.*<(
MW925E<Z>PT:RTZ-%C@4G^)FZFKQ55&,`#VIEU)Y$$DH&652:\XNM7OKJ=I&G
MD`)XPV-M9PBY]2(JYZ3M7VI>$Y4[3ZUYA]ON_P#GYE_[ZH:\N7_Y;R_]]5?U
M7S*Y#T.^U:TTZW:225"W9!][\J\[O[U[^]DG<%6D.5/M43.TARS$GU-%;4Z:
M@..@Z*22%MT3,I'/RG%6QKNI(H`NIE_6NL\,VT,ND1-+!&S9/)&:U?L=H?\`
MEA#^"U$ZJ3M8)S.!&O:M(<1W,S$]L5V^B"Z%A&]V6>5AGY^,5:6UM8Q^[AB%
M0WFHVME'F>9%`'`W<UC.2FK)$MW.=\<'!MD[L":9X*_X^KG_`'16/K&JMJMZ
MT^,1K\J*>"/>MCP3Q<7/0':*V:M3U';2QL^)P3H\P`R<CBN!$4O]QQ_P&O5&
M".,,%-,\B'^XE8PK<O0(RL8'@VSDM[*228%=YRJD8-.\:.BZ9&.[/6S/<VUJ
MN995C4=R:XKQ1K":C<I'$?W,8('U]:=-.4KB6LC$P?3O7J=F/W,/^X/Y"LC0
M+&U?2(&DAA<D=2.:V55=JJ`5"]`!1B'?0)STL>>^(P1K,_%4;63R+J*4](V#
M?D:]+>RLY&+26\3-ZD5ROC*W@MW@$2(H8=`*VI5.9<HX3OH=9%*LD:21\[P&
M_.N2\0W>JV-_*4GF6%C\I'0U)X=\2)!"+.]^ZOW9/Z5U"M:W:95XY5(R.<UB
MTZ;N+9W//_[=U0?\O4GY_P#UJ9+K6HR(R27,C*PY!_\`U5Z%]DM?^><7Y52U
MFVMTTRX*11@[>P]ZN-5=AIGG>6P`QS@UHZ!_R'-/_P"OB/\`]"%9X'`XK0T#
M_D.:?_U\1_\`H0K:K\+-C[NHHHKX4T/@&AJ*4]*^],STG1_^039_]<EK.\1:
M!<:M/%)"ZC:O\5&F>(M,@L+>*6Y5&5-K<&K?_"2Z5_S]K_WR:XGSQ=TCF][F
M.=_X0F^_OQ?E3X/!5QYL9FG0*/[HKH/^$ETG_G[7_ODU$WBC2!TNMW_`35>T
MJ=A\\C6CB6.-857"HN.:X[QQ<QR74,$?WHURU:%[XSMHXV2U1I7]6KC+BXFN
M)VFD;=*S;MU70IN]Y%0AK<W=,\.WNH6B3PW@B20XQS577-)NM-$/GW`EW'''
M-;N@:UIUGID4,\P60'=C%4/%NHV>H"W^RRAC&<\"G>7/L/4YS'>E!*-N4E6'
M3VI.U%;FA:75;Y5VK=3*H]&S4<MW<7!W3.[MZ,U0[:"*+"Y0[5N^#[M(=4VO
M\OF#`K"I\<C1.KJ<,IR*F:NK$GJDB+(A5AP1BN1O/!,C2[[6<!22VUA4NG>-
M(658KZ-P>@=16HOB?2F7)NL?[RUQVJ0V(Y'$Y_\`X0F^_OQ?E1_PA-]_SUB_
M*NC/B32O^?M?^^31_P`)+I/_`#]K_P!\FM/:5.PN>9S9\$7^/]?%Q[5A.C0L
MR,064E3BN_;Q)I1!'VM>GH:X&Z*M<2E6#)O)!'O6U-R>YK"_VAJW4\8VJ[*/
M8TOVRY_Y[O\`G4>VC;6EBQ_VJX_Y[2?G2,[/]]BWUIM%`!CO3UD>,YC=E/L<
M4RB@1+]KN?\`GX?\Z3[7<?\`/P_YU'1BBPN4<TDD@^9V;ZFDVY/2DHJD42I=
M3J-H=P,]C7J%N,P1DG)*+_(5Y7QD9/0YKO[;Q-I0CB22Y52H`/RGT%<V(BV]
M#&9ROB"ZFCU>=5D8#M@UEM/++_K'+8]35[7;F&\U2::$@H_((%9U:TOA+C\(
M[MSTIRRR1\H[+]#BF4511+]KN?\`GX?\Z:US.Z[7E9A]:9MHQ0+E%[5?T#_D
M.:?_`-?$?_H0K/K0T#_D.:?_`-?$?_H0J*OPLH^[J***^%-#X!H:BAONU]Z]
MC,^A_!O[+^G>)_"^GZW-KMS`UY`LI0(/ES6I_P`,E:)_T-DWY+7IW@B.2?X+
M:?'`K-+)I05%7J3LKY*/PZ^(ID8#0M>SD_P/ZU\M0Q-:K4FG6Y;#/1_&'[+.
MHZ'I-SJ6BZLFI^6I<P-'AB/4'/6J/P\_9\L_&G@<^))=8GMI"KGRD0=5[5[Y
M\)].U;1_AA9VWB+S!=QQ2&196^9%YP#^%4?@@MO=_#>8(56TDN;H*5[*7./T
MKGEF==*2YKV=KV%RGQ*R[2?8FDKZ0TCPW\!)-4BT'SI[Z_DD\H2N\@#2=.V!
MUKF/CY\'M+^',=CJ>BNXL[N3RFAE;)C<`D$'KV->]1S2#DJ<TTWM<#Q;WHP!
M7TAX5^$_PTT?P9'K?BJ\&H7+0":6..?E,C(4*ISFKGA+P5\%?B1-/INC:;?V
MMY&A<"220,!ZC)(-1/.:49.R;2W?0#YD[4E>OQ?"6PT/XV6G@[4"]WI\V'`)
M*ET(/4CW%>D^,OAA\&_`=S:3ZXMQ;Q3@I';K([;V_O<'/%5/-Z2:BDW?:P'R
MO17T?\4/@AX3T[PS:^)/#:26\+21EHS(S++&Q'KR.M='XD^!WPOT/P[;ZSJ0
MGTV!/+>:596;=D?=P<]:AYS1LGRO5V`^3=M+7U-X5^&_P7^(T-W:^&XK@W$"
M_,^^0,F>_P`W%8=Y\/\`X-?#N^.D^+=1NK_4"=V,N/+4]!\M5_;%._+RN_:P
M'SIUHKZ.^*OP/\)6'@67Q7X46:W2&,3!"[,DJ?0\UG_"OX2^`[_PB/$?BN_6
M>5E,AMEN-NQ1[#G-"S:C[-U+/TZ@>`T;:^E?#WAWX$>,-831=,TV^BO)<B(R
M-*H8^Q)KB/B1\$O^$8\=Z7H6DS.UIJK@0-)R\1[CW`JJ6:TI2Y9)J_<#R&CB
MOJ/6/A'\)/AEIELWBY[BXN)_E5F=_G8=<!/ZTZP^#OPG^(V@7%WX1>>UDCRB
MR>:_RN/4.?Y5#S>DU?D=N_09\M45['\)/@E%XQ\0:I;ZU.ZV.E3F!UC&#(X/
M0'TKLK_1OV?M(U"72KJWNS<POY;MF8A6Z=1Q3JYM24E"*;]!'S52U[U\9/@;
MH?AGPN/%?A>646@VEX9&W`JW0J>M;5_\%_!]O\''\316#C5/L(G$HF;&X@=L
MXJEFU%J,EU=AGS90H9F`3.XG`QWKN?@MX5TSQCX^LM)UB)IK2:-V9%?!X''3
MFO2/'GP^^'G@+XE:+:7=M+:Z+/"7F`D=B9,_+WS^57B,RIPFZ23N(\<U'P'X
MFTG3FU2^T2]M[/`/G,ORX/2L.WA6>XBB<[5D=4SZ9/6ON_QZO@\^`@OB,R#0
M"L>"I;./X>G-?-GQ!@^#TFD0+X+>9M1-Q&I4F093//WN*Y<)FKJQ:E%_+]1\
MH?$#X,Z'X0\%KKEGXC6\N/W?^C@K_$.>E>/GI7TI\6?A!X8\.?#:+5=*LIH[
MYW@4.\[N/FZC!..M3:7\#/`/@[P=#K_CF>:9G56DPY549A]T!:C#9G&$+R;;
M;ML!\R]:-M?4GACP!\#_`(BK<6GAZ.>.YB7+-YLBE??YC@UY+<?"J"S^*_\`
MPAEYJ:1V8D#M=,P7]V1D=>-U=E+-*4N9--/S%8\VQB@<'./>OIKQ'X-^"'@1
M;:VU.TNM1FE4_O(978G'=MI`%27?P0^'WC?P5-K_`(,%U9NJ2-$69F#,O52&
MSW%8K.*3?O1:7>P'`_!SX'V?Q/\`#]YJ-QJ<]J;><Q"-5_V0>OXUY;X@TM-&
MUN]TY)&D6VF:(.PQG:<5]2?LFQM'X,UI&&TIJ#*PQC!"`$5Q7PY^$>F?$7QY
MXGO-:DE^RV5ZRB%#@LQ)/-<U',G"M5E.7NH+'@7I17T?KFG?`?P_K,NBWFC:
MDUQ;R>5(X,NU6'&<YKF_C!\./`&CZ`-8\(:S;^:C+OL_M(D9E;N!G(KLHYM"
M<U%Q:OUMH!XG6AH'_(<T_P#Z^(__`$(50J_H'_(<T_\`Z^(__0A7HU?A8'W=
M1117PIH?`-#?=HHQGBOO69GW;\/;M]-^#^DWJ`.\&FK*H/LE>$G]KSQ6'(&C
MZ5U(Z-_C7%67QU\::9H*>'8KVW2TBA^SB,P@G9CU^E>?$$G=WSDUX.$RB/M*
MDJZO?8.8]5\5_M'>-/$^GRZ:7LK""<,LAMD.XK]23^E>Z_`#CX*KS_#<?R-?
M&G6N]\._&?QAX1\/?V+IMS;QV(W*%:($\]:TQF5\U%4Z*2UN!A^`\GQSHW7_
M`(_D_P#0A7TI^UC"D_ACP]%(<))J*JQ]`4-?*NFZA=:7J-O?VDFV>"02(2/X
MNU=5XT^*_BCQYIUO9Z]=QS06TOFIMC"G.".WM3Q6!G4JTYQV6X7/JC5+:#X:
M?#Z&\\*>&(M7N%BC7R88\M*#C+'`)/K69\*?&6M^*_$$K:OX"_L1XXB4O#`8
M^_*Y(KY^\/?'SQUX7TV&SM=32>VB7:BW,08JOH".?SJTW[2?Q$FNXY%U*W0X
M^6)8!M;ZUYTLHKZQLG?K<.8]2\5_\G2Z-_U[1_\`LU87[8`QK/A_''[I_P"8
MKRJ\^*?B:_\`%T7BVYN(VU.U01+(L8"CKCY>_6JGCGXBZ]X^GM9?$$\4TEN"
ML16,+@'Z5U87+:M.M";M9;AS$=GXLU^]GL].N]:OYK+S440M,2F`>!C.*^G?
MVCQ_Q9F/G^*#^E?(4,K6\\<\9P\9##ZBNU\3_&'Q9XST'^P]3NK>:S!4D+"%
M/R].:[,7E\IUJ<Z=K)W8KGIG['O_`"'=<_Z]T_\`0JXC]HD_\79U/O\`+'_*
MN:\$?$+7?`$US<>'[A(I+E`KEHPW0^]9OB?Q-J7BK6IM5U257O)2`[*@7/Y5
M,,)4^MRK=&K#YCZV\3D#]G9LG@Z:G\J/A_H&F^$/A/:ZOHFBIJ>H-:"9D5<R
M3N>V?Z5\WWOQJ\67/A@^&9[N#^SS"(#&(1NV_6CPA\9O&/@JQ33M+U,M;#YD
MBF0.!]">17G/*Z[A))];^H7/??`OCWQ'XK\6V=OK'PX.GPY)6\:W93;D#KDK
MC\J=\7[^*R^+'@>:9@D8E9<GU/%>,3?M)_$.XD1TU*"%5[)`O/YURGC3XE^(
M_'5Y:3ZY=H\MF287C380?PJZ645_:*4DDO4.8^@_VHO!^N^)X=&N=%TVXOD@
M+B18$WLN>^*X[X7?L_ZYK&C7-YJ^HZEX=97)2+;M)'J0>E<EHG[1/C_1(19I
MJ<=TJ(%1;B(,0/J,'\\TS7/VAO'^LV4EI+J45M%(I5O(B`)_&M*>#QE.#H1:
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M=SZM^+&DWWB#X,I:Z7:RWEP\,#+%$,LP`["O';WX`1>'?`UOXIU'4YX+Y?+=
MK-XL!7+#Y>><UR^@?'[QSX5T^+3K74(Y8(0%07,>\J/KZ5G>+_BYXP\9PHFK
MZB#;1R!EAAC"IN'()[G\:PHX#&4FX0:LW<.8^E_CA,D'PGT^60@(D]HSGT`/
M--^.&AZAXM^$MO#H5M)>S;X)A'#R64#J!WZU\V>)?C)XK\6Z`=!U6YMY;'Y2
M56$`_+P.:L>%?C;XZ\)6*V&GZF9;6%<B&=%<(/8GFLX91B(I3C:Z=PYC?^%G
MP-\2Z_J-R-275?#L4:#;+Y1C,A]/>MWP/\.=)M_CO+X?U._;6X[*V,VZXYWR
M<<$9.<9_2N6O?VE?B'?Q-$M_;6P88S'$,_G7`VGB?6+#7AK=M?W":F'+^>6R
MV>_/<>U=7U/&57+VC2]`N?6?Q-\<:[X-U*+2]"\`?VI:%`3,L!=,^F`*ZCP1
M>W&I>`7O+KP__8$\R3,]GLV[3S\V,=^M?,]M^TQ\0A$(A>6LC8QO,`R*JC]I
M#XA?9Y89-4BE1]P;=`O&>PKB>3XBRC97[W"Y[1^RISX4\0_]A-__`$$5S?P>
MA\3KXZ\7W'AZXTUH1?,MQ;W>X'[QPRX_&O)O!/Q@\4>`;"XM=(DMD@N9S-(9
M8@27(YZ>U9FB?$#Q)X=\17>M:5?O;7MRY:?8!L?//*GBMUE==\^WO!S'T?KO
MQ5\2Z;K%SI]U\+)]2,3[!<1(S+*/[P.P_P`^].^-'@WP_J_PPGU^?18-)U)(
MHYE8(%>,DC*-C&>N*\C'[4'Q"11NN+#ZO!S^E<KXS^*GB_QU:"#6M3>2T!W>
M3&H1"?<#K^-*CE6(52,K)6ZW8<QQF3M!`.6Y/I6AH'_(<T__`*^(_P#T(50Q
=Q5_0?^0YI_\`U\1_^A"OH:OP,#[NHHHKX4T/_]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
